Program
Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911
Its studies are led by Mabwell (Shanghai) Bioscience.
Furthest: phase 2, since Sep 24, 20252 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience | 22 open or running | phase 2since Sep 24, 2025 | Sep 24, 2025 | Jul 2027phase 2 · NCT07216560 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2025First study: phase 2 study in GI CancersFirst studyNCT07216560 · 200 planned · United States
- Nov 16, 2025Phase 2 study in Solid TumorsNCT07265622 · 200 planned · China
Ahead
- Jul 2027Primary completion: phase 2 study in Solid TumorsNCT07265622
- Jul 2027Primary completion: phase 2 study in GI CancersNCT07216560
TargetBeta
CDH17 →read by rule
“An antibody-drug conjugate (ADC) composed of Mab0727, a monoclonal antibody targeting the tumor-associated antigen (TAA) cadherin-17 (CDH17) ”NCIt, by rule
Other programs on CDH17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CDH17 Antibody-drug Conjugate HS-20110 | Hansoh Pharmaceutical Group | phase 2 | 2 |
| AMT-676rule | multitude-therapeutics-inc | phase 2 | 2 |
| Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324rule | dualitybio-inc | phase 2 | 1 |
| LM-350 | Sino Biopharmaceutical | phase 2 | 1 |
| Anti-CDH17 Antibody-drug Conjugate YL217rule | MediLink Therapeutics (Suzhou) | phase 1 | 1 |
| Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rule | arrivent-biopharma-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07265622Solid Tumors · China | 2 | Recruiting | Jul 2027 | 200 |
| NCT07216560GI Cancers · United States | 2 | Recruiting | Jul 2027 | 200 |
How it is read
Names in the registry
- “7MW4911”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.